GlobeNewswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 18:00:00时区推断·⟳ 抓取 18:01:41·⚡ 决策 08-04 18:46:20 +44m39s·84.4 天前
Biodesix宣布参加Canaccord Genuity年度成长会议
公司仅公告管理层将参加投资者会议和炉边谈话，没有披露订单、产品、监管、财务或指引增量。
📄 原文GlobeNewswire Biotechnology↗ 原文
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions com…
不做 Biodesix（BDSX.US）
例行投关会议参与公告，无明确方向、无业绩或商业化增量，不能形成正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 low ↗
关键理由
- 公司仅公告管理层将参加投资者会议和炉边谈话，没有披露订单、产品、监管、财务或指引增量。
主要风险
- 该类例行投关日程通常不构成短线可交易催化。
原文全文
展开原文 · 1,527 字
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity’s 46th Annual Growth Conference, which will be held from August 11-12, 2026.
Canaccord Genuity’s 46th Annual Growth Conference
Fireside Chat Date: Wednesday, August 12, 2026
Fireside Chat Time: 3:30 PM ET
Location: InterContinental Boston, Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix website at Biodesix.com.
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
Canaccord Genuity’s 46th Annual Growth Conference
Fireside Chat Date: Wednesday, August 12, 2026
Fireside Chat Time: 3:30 PM ET
Location: InterContinental Boston, Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of Biodesix website at Biodesix.com.
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。